CA2192209C - Traitement de la nevrite optique - Google Patents

Traitement de la nevrite optique Download PDF

Info

Publication number
CA2192209C
CA2192209C CA002192209A CA2192209A CA2192209C CA 2192209 C CA2192209 C CA 2192209C CA 002192209 A CA002192209 A CA 002192209A CA 2192209 A CA2192209 A CA 2192209A CA 2192209 C CA2192209 C CA 2192209C
Authority
CA
Canada
Prior art keywords
arginine
amino
nitro
ethambutol
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA002192209A
Other languages
English (en)
Other versions
CA2192209A1 (fr
Inventor
Evan Benjamin Dreyer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Massachusetts Eye and Ear Infirmary
Original Assignee
Massachusetts Eye and Ear Infirmary
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/264,728 external-priority patent/US5597809A/en
Application filed by Massachusetts Eye and Ear Infirmary filed Critical Massachusetts Eye and Ear Infirmary
Publication of CA2192209A1 publication Critical patent/CA2192209A1/fr
Application granted granted Critical
Publication of CA2192209C publication Critical patent/CA2192209C/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne de procédés de traitement de la névrite optique, consistant à administrer un agent de protection contre les dommages de cellules rétiniènes induits par le glutamate à un mammifère présentant des risques de développement d'une névrite optique
CA002192209A 1994-06-23 1995-06-07 Traitement de la nevrite optique Expired - Lifetime CA2192209C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/264,728 US5597809A (en) 1994-06-23 1994-06-23 Treatment of optic neuritis
US08/264,728 1994-06-23
PCT/US1995/007259 WO1996000073A1 (fr) 1994-06-23 1995-06-07 Traitement de la nevrite optique

Publications (2)

Publication Number Publication Date
CA2192209A1 CA2192209A1 (fr) 1996-01-04
CA2192209C true CA2192209C (fr) 2007-03-13

Family

ID=38007982

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002192209A Expired - Lifetime CA2192209C (fr) 1994-06-23 1995-06-07 Traitement de la nevrite optique

Country Status (1)

Country Link
CA (1) CA2192209C (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2769902B2 (es) * 2018-12-28 2020-12-04 Consejo Superior Investigacion Uso de secoiridoides para el tratamiento de la neuritis óptica.

Also Published As

Publication number Publication date
CA2192209A1 (fr) 1996-01-04

Similar Documents

Publication Publication Date Title
US5597809A (en) Treatment of optic neuritis
US5922773A (en) Glaucoma treatment
US6482854B1 (en) Glaucoma treatment
US6380261B1 (en) Calcium blockers to treat proliferative vitreoretinopathy
CA1332811C (fr) Traitement de l'hypertension oculaire par des bloqueurs des canaux calciques de type i
US5506231A (en) Treatment of aids dementia, myelopathy and blindness
CA2492081C (fr) Compositions pharmaceutiques comprenant du dextromethorphan et de la quinidine pour traiter des troubles neurologiques
CA2143752C (fr) Methode de prevention des dommages neuronaux medies par le recepteur nmda
KR101891144B1 (ko) Lfa-1 저해제 제형
US20120004265A1 (en) Ophthalmic Compositions and Methods of Using the Same
EP0432994A2 (fr) Antagonistes d'acides aminés excitateurs comme médicaments anti-émétiques
BRPI0710085B1 (pt) composições oftálmicas e seus kits
PT1732548E (pt) Métodos de utilização de composições de aminopiridina de libertação contínua
WO1992003137A1 (fr) Traitement des demences, des myelopathies, des neuropathies peripheriques et des pertes de vision liees au sida
EP1267849B1 (fr) Substances diminuant la reapparition de l'usage de drogues
Nigrin et al. Listeria monocytogenes endophthalmitis in an immune-suppressed host
WO2007049825A1 (fr) Antagoniste du recepteur p2x4antagoniste du recepteur p2x4antagoniste du recepteur p2x4
Rivera-Calimlim et al. pathic parkinsonism generally respond better to
Manocha et al. Acute Onset Blindness in a Tubercular Meningitis Patient on Antitubercular Treatment: A Rare Case
HK1145632A (en) 1-amino-alkylcyclohexane derivatives for the treatment and prevention of hearing loss
HK1110207B (en) Ophthalmic compositions and methods of using the same
HK1214963B (en) Lfa-1 inhibitor formulations
MX2011013736A (es) Composiciones oftalmicas que comprenden combinaciones de un inhibidor de anhidrasa carbonica y antagonista beta adrenergicos.

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20150608